



THOMSON MEDICAL GROUP LIMITED

(Incorporated in the Republic of Singapore)

(Company Registration No. 199908381D)

INTERESTED PERSONS TRANSACTIONS – USE OF MARKET CAPITALISATION AS BASIS FOR COMPUTING MATERIALITY THRESHOLD IN RESPECT OF RULES 905 AND 906 OF THE LISTING MANUAL

The Board of Directors of Thomson Medical Group Limited (the "**Company**", and together with its subsidiaries, the "**Group**") wishes to announce that due to the Group's latest audited net tangible asset ("**NTA**") position being negative (at approximately negative \$266 million) as at 30 June 2026, based on Rules 905(4) and 906(3) of the Listing Manual (the "**Listing Manual**") of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"), the Company has consulted with the SGX-ST on the appropriate benchmark to calculate the relevant thresholds in Rules 905 and 906 of the Listing Manual.

Given that the NTA of the Group is negative, the Company is of the view that market capitalisation is a more meaningful alternative reference point to determine the materiality thresholds in Rules 905 and 906 of the Listing Manual as it is reflective of the scale of the business as well as valuation of the Group.

The SGX-ST has, on 29 September 2026, confirmed that, it has no objection to the Company's proposed use of market capitalisation, as an alternative reference point in place of the Group's audited net tangible assets, for the purpose of Rules 905 and 906 of the Listing Manual in respect of the financial year ending 30 June 2027. Market capitalisation shall be computed using the average of the Company's daily market capitalisation during the last month of the immediately preceding financial year, calculated based on the total number of issued shares (excluding treasury shares) multiplied by the volume-weighted average price for each trading day in that month.

By Order of the Board
THOMSON MEDICAL GROUP LIMITED

Dr Heng Jun Li Melvin
Executive Director and Group Chief Executive Officer
29 September 2026